APELOA(000739) 证券时报网·2025-03-11 01:37Group 1: Financial Performance - In 2024, the company achieved operating revenue of 12.022 billion yuan, a year-on-year increase of 4.77% [1] - The net profit attributable to shareholders was 1.031 billion yuan, a decrease of 2.29% year-on-year, while the net profit after deducting non-recurring gains and losses was 984 million yuan, down 4.09% [1] - Operating cash flow was 1.209 billion yuan, reflecting a strong performance with a year-on-year growth of 17.20% [1] - The company plans to distribute a cash dividend of 3.56 yuan per 10 shares, totaling approximately 412 million yuan [1] Group 2: Business Strategy and Market Position - The company focuses on refining its raw materials business strategy, aiming to supply high-quality and competitive APIs to global pharmaceutical companies [1] - The API business showed steady progress, with a sales revenue of 8.651 billion yuan, an increase of 8.32% year-on-year [1] - The company has developed over 50 new clients, enhancing its market share in strategic products [1] Group 3: CDMO Development - Since establishing the CDMO division, the company aims to become a leading global innovative drug R&D and production enterprise [2] - The number of quoted projects reached 1,601, a year-on-year increase of 77%, with ongoing projects totaling 996, up 35% [2] - The CDMO R&D center in Boston commenced operations in September 2024, enhancing service capabilities in the North American market [2] Group 4: Pharmaceutical Business - The pharmaceutical business generated revenue of 1.256 billion yuan, a slight increase of 0.51% year-on-year, with a gross profit of 764 million yuan, reflecting a growth of 15.02% [2] - The gross margin for the pharmaceutical business was 60.81% [2] - The company is advancing a multi-product strategy, with over 120 formulation varieties and 64 projects under research [2] Group 5: R&D Investment - R&D investment reached 641 million yuan in 2024, a year-on-year increase of 2.66%, accounting for 5.34% of revenue [3] - The company has received approvals for 12 API varieties and 5 formulations domestically, with 2 formulations approved by the FDA [3] - A new international high-end formulation workshop is planned to enhance production capacity, currently in the design phase [3]